Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing, page-21

I feel an inevitable price climb. How can we not from these depths. (could have said that at 10c eh)

Regardless of who is appointed the next CEO, the market likes clarity, so this should push our price up, or if it's a winning name, a substantial rerate.

Then we have trial news such as this which is edging closer and closer towards first dose, and then last dose, which should get the FOMO firmly in play. Where would we be prior to mid 24 results and tox study release? anyone's guess, a few bags from here at least I should think.

We've got LMGD going on and possible cash from co-labs or SALEs hopefully coming from long covid. This is important for obvious reasons but a lot to do with 'coming through what they said might happen'. So the next time they say 'in negotiations' people take notice.

We've got possible competition fails in two weeks and four weeks.

an interesting time that's for sure.